Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

被引:37
作者
Galimberti, Sara [1 ]
Petrini, Mario [1 ]
Barate, Claudia [2 ]
Ricci, Federica [1 ]
Balducci, Serena [1 ]
Grassi, Susanna [1 ]
Guerrini, Francesca [1 ]
Ciabatti, Elena [1 ]
Mechelli, Sandra [2 ]
Di Paolo, Antonello [1 ]
Baldini, Chiara [1 ]
Baglietto, Laura [1 ]
Macera, Lisa [3 ]
Spezia, Pietro Giorgio [3 ]
Maggi, Fabrizio [3 ]
机构
[1] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[2] AOUP, Hematol, Pisa, Italy
[3] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
CML; TKIs; imatinib; nilotinib; TTV; immunity; NanoString; COVID-19; TT VIRUS; COVID-19; CORONAVIRUS; INTERFERON; EFFICACY; CELLS; CD28;
D O I
10.3389/fonc.2020.01428
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
SARS-CoV-2 is the viral agent responsible for the pandemic that in the first months of 2020 caused about 400,000 deaths. Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML), have been proposed on the basis of their antiviral action already demonstrated against SARS-CoV-1. Very few cases of COVID-19 have been reported in Ph+ ALL and in CML Italian cohorts; authors suggested that this low rate of infections might depend on the use of TKIs, but the biological causes of this phenomenon remain unknown. In this study, the CML model was used to test if TKIs would sustain or not the viral replication and if they could damage patient immunity. Firstly, the infection and replication rate of torquetenovirus (TTV), whose load is inversely proportional to the host immunological control, have been measured in CML patients receiving nilotinib. A very low percentage of subjects were infected at baseline, and TTV did not replicate or at least showed a low replication rate during the follow-up, with a mean load comparable to the measured one in healthy subjects. Then, after gene expression profiling experiments, we found that several "antiviral" genes, such asCD28andIFN gamma, were upregulated, while genes with "proviral" action, such asARG-1, CEACAM1, andFUT4, were less expressed during treatment with imatinib, thus demonstrating that TKIs are not detrimental from the immunological point of view. To sum up, our data could offer some biological explanations to the low COVID-19 occurrence in Ph+ ALL and CML patients and sustain the use of TKIs in COVID-19, as already proposed by several international ongoing studies.
引用
收藏
页数:9
相关论文
共 69 条
  • [1] Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Abou Dalle, Iman
    Jabbour, Elias
    Short, Nicholas J.
    Ravandi, Farhad
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (01)
  • [2] Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages
    Arlauckas, Sean P.
    Garren, Seth B.
    Garris, Chris S.
    Kohler, Rainer H.
    Oh, Juhyun
    Pittet, Mikael J.
    Weissleder, Ralph
    [J]. THERANOSTICS, 2018, 8 (21): : 5842 - 5854
  • [3] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
    Baccarani, Michele
    Deininger, Michael W.
    Rosti, Gianantonio
    Hochhaus, Andreas
    Soverini, Simona
    Apperley, Jane F.
    Cervantes, Francisco
    Clark, Richard E.
    Cortes, Jorge E.
    Guilhot, Francois
    Hjorth-Hansen, Henrik
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Larson, Richard A.
    Lipton, Jeffrey H.
    Mahon, Francois-Xavier
    Martinelli, Giovanni
    Mayer, Jiri
    Mueller, Martin C.
    Niederwieser, Dietger
    Pane, Fabrizio
    Radich, Jerald P.
    Rousselot, Philippe
    Saglio, Giuseppe
    Saussele, Susanne
    Schiffer, Charles
    Silver, Richard
    Simonsson, Bengt
    Steegmann, Juan-Luis
    Goldman, John M.
    Hehlmann, Ruediger
    [J]. BLOOD, 2013, 122 (06) : 872 - 884
  • [4] Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans
    Bendinelli, M
    Pistello, M
    Maggi, F
    Fornai, C
    Freer, G
    Vatteroni, ML
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (01) : 98 - +
  • [5] BRECCIA M, 2020, LEUKEMIA 0618
  • [6] Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2
    Brennan, Faith H.
    Jogia, Trisha
    Gillespie, Ellen R.
    Blomster, Linda, V
    Li, Xaria X.
    Nowlan, Bianca
    Williams, Gail M.
    Jacobson, Esther
    Osborne, Geoff W.
    Meunier, Frederic A.
    Taylor, Stephen M.
    Campbell, Kate E.
    MacDonald, Kelli Pa
    Levesque, Jean-Pierre
    Woodruff, Trent M.
    Ruitenberg, Marc J.
    [J]. JCI INSIGHT, 2019, 4 (09)
  • [7] Torque Teno virus:: any pathological role in liver transplanted patients?
    Burra, Patrizia
    Masier, Annalisa
    Boldrin, Caterina
    Calistri, Arianna
    Andreoli, Elisabetta
    Senzolo, Marco
    Zorzi, Manuel
    Sgarabotto, Dino
    Guido, Maria
    Cillo, Umberto
    Canova, Daniele
    Bendinelli, Mauro
    Pistello, Mauro
    Maggi, Fabrizio
    Palu, Giorgio
    [J]. TRANSPLANT INTERNATIONAL, 2008, 21 (10) : 972 - 979
  • [8] Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
    Chan, Jasper Fuk-Woo
    Kok, Kin-Hang
    Zhu, Zheng
    Chu, Hin
    To, Kelvin Kai-Wang
    Yuan, Shuofeng
    Yuen, Kwok-Yung
    [J]. EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 221 - 236
  • [9] Chang Xuan, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P1047
  • [10] Functions of the FAK family kinases in T cells: beyond actin cytoskeletal rearrangement
    Chapman, Nicole M.
    Houtman, Jon C. D.
    [J]. IMMUNOLOGIC RESEARCH, 2014, 59 (1-3) : 23 - 34